SEC Form 4 · accession 0001209191-17-049317
EAGLE PHARMACEUTICALS, INC. · EGRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Pete A. Meyers
Officer — Chief Financial Officer
Period of report
Aug 16, 2017
Accepted (ET)
Aug 16, 2017 · 8:30 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000827871
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 16, 2017 | P | 350 | $55.4468 | A | 700 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $55.4294 to $55.47, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4.